DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack By Nick Paul Taylor Apr 15, 2025 4:45am Boehringer Ingelheim Cue Biopharma autoimmune disease Licensing deals ...

New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design.

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...

B cells are white blood cells, produced in the bone marrow, that neutralize pathogens – such as bacteria, viruses and cancer cells – and tag them for removal from the body. Memory B cells are ...

For example, results from the phase 3 GOYA study of patients with aggressive B-cell lymphoma showed that an end-of-therapy PET scan showed a 74% reduced risk of death (HR, 0.26; 95% CI, 0.19-0.38 ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among chi ...

SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive ...

Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined w ...

In a new study, researchers examined the efficacy and impact of CD19 CAR T cell therapy on B cells, specifically exploring its ability to deplete B cells in deep tissues and understand the therapeutic ...

Merck on Friday announced an agreement with Shanghai-based Curon Biopharmaceutical, paying $700 million upfront to buy CN201, an investigational bispecific antibody for B cell-associated diseases.